![Thomas Rowland](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Thomas Rowland
President at Arbor Pharmaceuticals LLC
Net worth: 2 M $ as of 30/05/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Edward Schutter | M | 72 |
Arbor Pharmaceuticals LLC
![]() Arbor Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Arbor Pharmaceuticals LLC develops pharmaceutical products, which focuses on cardiovascular, hospital and pediatric markets. It offers edarbyclor, cetylev, horizant, zenzedi, evekeo, sklice, and eryhromycin. The company was founded by Jarrett T. Disbrow and Edward J. Schutter and is headquartered in Atlanta, GA. | - |
Ali Satvat | M | 46 |
Arbor Pharmaceuticals LLC
![]() Arbor Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Arbor Pharmaceuticals LLC develops pharmaceutical products, which focuses on cardiovascular, hospital and pediatric markets. It offers edarbyclor, cetylev, horizant, zenzedi, evekeo, sklice, and eryhromycin. The company was founded by Jarrett T. Disbrow and Edward J. Schutter and is headquartered in Atlanta, GA. | 9 years |
Steven D. Caras | M | - |
Arbor Pharmaceuticals LLC
![]() Arbor Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Arbor Pharmaceuticals LLC develops pharmaceutical products, which focuses on cardiovascular, hospital and pediatric markets. It offers edarbyclor, cetylev, horizant, zenzedi, evekeo, sklice, and eryhromycin. The company was founded by Jarrett T. Disbrow and Edward J. Schutter and is headquartered in Atlanta, GA. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Russell Ellison | M | 76 |
Ventrus Biosciences, Inc.
![]() Ventrus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ventrus Biosciences, Inc. is a development stage specialty pharmaceutical company engages in development of late-stage prescription drugs for gastrointestinal disorders, specifically hemorrhoidal disease, anal fissures, and fecal incontinence. Its major pharmaceutical progress made in the gastrointestinal therapeutic areas of gastroesophageal reflux, peptic ulcer disease, and inflammatory bowel disease. Ventrus Biosciences products includes VEN 307 (topical diltiazem), is intended to treat pain associated with anal fissures and VEN 308 (topical phenylephrine), is intended to treat fecal incontinence. The company was founded on October 10, 2005 and is headquartered in New York, NY. | - |
David Barrett | M | 48 |
Ventrus Biosciences, Inc.
![]() Ventrus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ventrus Biosciences, Inc. is a development stage specialty pharmaceutical company engages in development of late-stage prescription drugs for gastrointestinal disorders, specifically hemorrhoidal disease, anal fissures, and fecal incontinence. Its major pharmaceutical progress made in the gastrointestinal therapeutic areas of gastroesophageal reflux, peptic ulcer disease, and inflammatory bowel disease. Ventrus Biosciences products includes VEN 307 (topical diltiazem), is intended to treat pain associated with anal fissures and VEN 308 (topical phenylephrine), is intended to treat fecal incontinence. The company was founded on October 10, 2005 and is headquartered in New York, NY. | - |
Mark Auerbach | M | 85 |
Ventrus Biosciences, Inc.
![]() Ventrus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ventrus Biosciences, Inc. is a development stage specialty pharmaceutical company engages in development of late-stage prescription drugs for gastrointestinal disorders, specifically hemorrhoidal disease, anal fissures, and fecal incontinence. Its major pharmaceutical progress made in the gastrointestinal therapeutic areas of gastroesophageal reflux, peptic ulcer disease, and inflammatory bowel disease. Ventrus Biosciences products includes VEN 307 (topical diltiazem), is intended to treat pain associated with anal fissures and VEN 308 (topical phenylephrine), is intended to treat fecal incontinence. The company was founded on October 10, 2005 and is headquartered in New York, NY. | - |
Joseph Felder | M | 63 |
Ventrus Biosciences, Inc.
![]() Ventrus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ventrus Biosciences, Inc. is a development stage specialty pharmaceutical company engages in development of late-stage prescription drugs for gastrointestinal disorders, specifically hemorrhoidal disease, anal fissures, and fecal incontinence. Its major pharmaceutical progress made in the gastrointestinal therapeutic areas of gastroesophageal reflux, peptic ulcer disease, and inflammatory bowel disease. Ventrus Biosciences products includes VEN 307 (topical diltiazem), is intended to treat pain associated with anal fissures and VEN 308 (topical phenylephrine), is intended to treat fecal incontinence. The company was founded on October 10, 2005 and is headquartered in New York, NY. | - |
Leslie B. Zacks | M | 55 |
Arbor Pharmaceuticals LLC
![]() Arbor Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Arbor Pharmaceuticals LLC develops pharmaceutical products, which focuses on cardiovascular, hospital and pediatric markets. It offers edarbyclor, cetylev, horizant, zenzedi, evekeo, sklice, and eryhromycin. The company was founded by Jarrett T. Disbrow and Edward J. Schutter and is headquartered in Atlanta, GA. | 6 years |
Anthony Altig | M | 68 |
Ventrus Biosciences, Inc.
![]() Ventrus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ventrus Biosciences, Inc. is a development stage specialty pharmaceutical company engages in development of late-stage prescription drugs for gastrointestinal disorders, specifically hemorrhoidal disease, anal fissures, and fecal incontinence. Its major pharmaceutical progress made in the gastrointestinal therapeutic areas of gastroesophageal reflux, peptic ulcer disease, and inflammatory bowel disease. Ventrus Biosciences products includes VEN 307 (topical diltiazem), is intended to treat pain associated with anal fissures and VEN 308 (topical phenylephrine), is intended to treat fecal incontinence. The company was founded on October 10, 2005 and is headquartered in New York, NY. | - |
Monil Shah | M | - |
Ventrus Biosciences, Inc.
![]() Ventrus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ventrus Biosciences, Inc. is a development stage specialty pharmaceutical company engages in development of late-stage prescription drugs for gastrointestinal disorders, specifically hemorrhoidal disease, anal fissures, and fecal incontinence. Its major pharmaceutical progress made in the gastrointestinal therapeutic areas of gastroesophageal reflux, peptic ulcer disease, and inflammatory bowel disease. Ventrus Biosciences products includes VEN 307 (topical diltiazem), is intended to treat pain associated with anal fissures and VEN 308 (topical phenylephrine), is intended to treat fecal incontinence. The company was founded on October 10, 2005 and is headquartered in New York, NY. | 3 years |
Myron Holubiak | M | 77 |
Ventrus Biosciences, Inc.
![]() Ventrus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ventrus Biosciences, Inc. is a development stage specialty pharmaceutical company engages in development of late-stage prescription drugs for gastrointestinal disorders, specifically hemorrhoidal disease, anal fissures, and fecal incontinence. Its major pharmaceutical progress made in the gastrointestinal therapeutic areas of gastroesophageal reflux, peptic ulcer disease, and inflammatory bowel disease. Ventrus Biosciences products includes VEN 307 (topical diltiazem), is intended to treat pain associated with anal fissures and VEN 308 (topical phenylephrine), is intended to treat fecal incontinence. The company was founded on October 10, 2005 and is headquartered in New York, NY. | - |
Jonathan Heath McGrael | M | - |
Arbor Pharmaceuticals LLC
![]() Arbor Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Arbor Pharmaceuticals LLC develops pharmaceutical products, which focuses on cardiovascular, hospital and pediatric markets. It offers edarbyclor, cetylev, horizant, zenzedi, evekeo, sklice, and eryhromycin. The company was founded by Jarrett T. Disbrow and Edward J. Schutter and is headquartered in Atlanta, GA. | 5 years |
Brian K. Adams | M | - |
Arbor Pharmaceuticals LLC
![]() Arbor Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Arbor Pharmaceuticals LLC develops pharmaceutical products, which focuses on cardiovascular, hospital and pediatric markets. It offers edarbyclor, cetylev, horizant, zenzedi, evekeo, sklice, and eryhromycin. The company was founded by Jarrett T. Disbrow and Edward J. Schutter and is headquartered in Atlanta, GA. | - |
Haitham Al-Terkait | M | - |
Metropolitan State University of Denver
| 4 years |
Carole J. Slinkard | F | - |
Metropolitan State University of Denver
| 4 years |
Derek Manning | M | - |
Metropolitan State University of Denver
| 4 years |
Mark Thompson | M | - |
Metropolitan State University of Denver
| 2 years |
Brian Haack | M | - |
Metropolitan State University of Denver
| 4 years |
Jason Wild | M | 51 |
Arbor Pharmaceuticals LLC
![]() Arbor Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Arbor Pharmaceuticals LLC develops pharmaceutical products, which focuses on cardiovascular, hospital and pediatric markets. It offers edarbyclor, cetylev, horizant, zenzedi, evekeo, sklice, and eryhromycin. The company was founded by Jarrett T. Disbrow and Edward J. Schutter and is headquartered in Atlanta, GA. | 11 years |
Lincoln Blaine Yersin | M | - |
Metropolitan State University of Denver
| 3 years |
Todd Sone | M | 53 |
Arbor Pharmaceuticals LLC
![]() Arbor Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Arbor Pharmaceuticals LLC develops pharmaceutical products, which focuses on cardiovascular, hospital and pediatric markets. It offers edarbyclor, cetylev, horizant, zenzedi, evekeo, sklice, and eryhromycin. The company was founded by Jarrett T. Disbrow and Edward J. Schutter and is headquartered in Atlanta, GA. | 2 years |
Ali Fardan Ali Al-Fardan | M | 58 |
Metropolitan State University of Denver
| 4 years |
Ted Ott | M | - |
Metropolitan State University of Denver
| 4 years |
J. William Conway | M | - |
Metropolitan State University of Denver
| 4 years |
Laurence J. Downey | M | - |
Arbor Pharmaceuticals LLC
![]() Arbor Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Arbor Pharmaceuticals LLC develops pharmaceutical products, which focuses on cardiovascular, hospital and pediatric markets. It offers edarbyclor, cetylev, horizant, zenzedi, evekeo, sklice, and eryhromycin. The company was founded by Jarrett T. Disbrow and Edward J. Schutter and is headquartered in Atlanta, GA. | 5 years |
Richard Cohen | M | 73 |
Ventrus Biosciences, Inc.
![]() Ventrus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ventrus Biosciences, Inc. is a development stage specialty pharmaceutical company engages in development of late-stage prescription drugs for gastrointestinal disorders, specifically hemorrhoidal disease, anal fissures, and fecal incontinence. Its major pharmaceutical progress made in the gastrointestinal therapeutic areas of gastroesophageal reflux, peptic ulcer disease, and inflammatory bowel disease. Ventrus Biosciences products includes VEN 307 (topical diltiazem), is intended to treat pain associated with anal fissures and VEN 308 (topical phenylephrine), is intended to treat fecal incontinence. The company was founded on October 10, 2005 and is headquartered in New York, NY. | - |
John Dietrich | M | 77 |
Ventrus Biosciences, Inc.
![]() Ventrus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ventrus Biosciences, Inc. is a development stage specialty pharmaceutical company engages in development of late-stage prescription drugs for gastrointestinal disorders, specifically hemorrhoidal disease, anal fissures, and fecal incontinence. Its major pharmaceutical progress made in the gastrointestinal therapeutic areas of gastroesophageal reflux, peptic ulcer disease, and inflammatory bowel disease. Ventrus Biosciences products includes VEN 307 (topical diltiazem), is intended to treat pain associated with anal fissures and VEN 308 (topical phenylephrine), is intended to treat fecal incontinence. The company was founded on October 10, 2005 and is headquartered in New York, NY. | 2 years |
Terrance C. Coyne | M | - |
Ventrus Biosciences, Inc.
![]() Ventrus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ventrus Biosciences, Inc. is a development stage specialty pharmaceutical company engages in development of late-stage prescription drugs for gastrointestinal disorders, specifically hemorrhoidal disease, anal fissures, and fecal incontinence. Its major pharmaceutical progress made in the gastrointestinal therapeutic areas of gastroesophageal reflux, peptic ulcer disease, and inflammatory bowel disease. Ventrus Biosciences products includes VEN 307 (topical diltiazem), is intended to treat pain associated with anal fissures and VEN 308 (topical phenylephrine), is intended to treat fecal incontinence. The company was founded on October 10, 2005 and is headquartered in New York, NY. | 2 years |
Shannon Crespin | F | - |
Metropolitan State University of Denver
| 5 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 29 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Thomas Rowland
- Personal Network